Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Key Takeaways PFE's oncology revenues rose 7% in Q1 2025, aided by Xtandi, Lorbrena, Padcev and Braftovi-Mektovi. The 2023 Seagen acquisition added four ADCs and next-gen candidates to PFE's cancer drug lineup. PFE's 2025 EPS estimate has risen to $3.06, while its forward P/E of 7.77 remains below the industry average.Pfizer (PFE) is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates wit ...